CL2020001335A1 - Métodos de tratamiento de la insuficiencia cardiaca con fracción de eyección reducida con dapagliflozina - Google Patents
Métodos de tratamiento de la insuficiencia cardiaca con fracción de eyección reducida con dapagliflozinaInfo
- Publication number
- CL2020001335A1 CL2020001335A1 CL2020001335A CL2020001335A CL2020001335A1 CL 2020001335 A1 CL2020001335 A1 CL 2020001335A1 CL 2020001335 A CL2020001335 A CL 2020001335A CL 2020001335 A CL2020001335 A CL 2020001335A CL 2020001335 A1 CL2020001335 A1 CL 2020001335A1
- Authority
- CL
- Chile
- Prior art keywords
- heart failure
- dapagliflozin
- methods
- ejection fraction
- reduced ejection
- Prior art date
Links
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 title abstract 3
- 229960003834 dapagliflozin Drugs 0.000 title abstract 3
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 abstract 7
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 abstract 2
- 230000034994 death Effects 0.000 abstract 2
- 231100000517 death Toxicity 0.000 abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 230000003862 health status Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893849P | 2019-08-30 | 2019-08-30 | |
| US201962930673P | 2019-11-05 | 2019-11-05 | |
| US201962946625P | 2019-12-11 | 2019-12-11 | |
| US202062960756P | 2020-01-14 | 2020-01-14 | |
| US202062969181P | 2020-02-03 | 2020-02-03 | |
| US202062985407P | 2020-03-05 | 2020-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020001335A1 true CL2020001335A1 (es) | 2021-07-09 |
Family
ID=69784449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020001335A CL2020001335A1 (es) | 2019-08-30 | 2020-05-20 | Métodos de tratamiento de la insuficiencia cardiaca con fracción de eyección reducida con dapagliflozina |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10973836B2 (https=) |
| EP (1) | EP4021507A1 (https=) |
| JP (4) | JP7756487B2 (https=) |
| KR (3) | KR102359799B1 (https=) |
| CN (1) | CN112752582A (https=) |
| AU (4) | AU2020202887B2 (https=) |
| BR (1) | BR112020008705A2 (https=) |
| CA (1) | CA3079175A1 (https=) |
| CL (1) | CL2020001335A1 (https=) |
| CR (1) | CR20200224A (https=) |
| IL (1) | IL274020A (https=) |
| JO (1) | JOP20200098A1 (https=) |
| MX (2) | MX2020005388A (https=) |
| PE (1) | PE20211267A1 (https=) |
| PH (1) | PH12020551141A1 (https=) |
| SG (1) | SG11202003971RA (https=) |
| TW (3) | TWI786398B (https=) |
| WO (1) | WO2021037400A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021000139A2 (pt) | 2018-07-19 | 2021-04-06 | Astrazeneca Ab | Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma |
| WO2021037400A1 (en) | 2019-08-30 | 2021-03-04 | Astrazeneca Ab | Methods of treating heart failure with reduced ejection fraction with dapagliflozin |
| EP4138826A1 (en) * | 2020-04-22 | 2023-03-01 | Bayer Aktiengesellschaft | Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases |
| US20240100013A1 (en) * | 2021-01-04 | 2024-03-28 | Lexicon Pharmaceuticals, Inc. | Sotagliflozin for improving left atrial function |
| US20250108065A1 (en) | 2022-01-26 | 2025-04-03 | Astrazeneca Ab | Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapagliflozin |
| JP7396579B2 (ja) * | 2022-01-31 | 2023-12-12 | 壽製薬株式会社 | 左室駆出率が保たれた心不全に対する医薬組成物 |
| WO2023175573A1 (en) * | 2022-03-17 | 2023-09-21 | Zydus Lifesciences Limited | Pharmaceutical compositions comprising a β-blocker and an sglt2 inhibitor |
| US20250205317A1 (en) * | 2022-03-28 | 2025-06-26 | University Of Maryland, Baltimore | Methods and compositions for the treatment of stroke |
| CR20250112A (es) * | 2022-09-01 | 2025-08-18 | Aztrazeneca Ab | Combinación de ihnibidores de sglt2 y moduladores del receptor mineralcorticoide para usar en el tratamiento de enfermedades cardiorrenales |
| EP4640213A1 (en) * | 2022-12-20 | 2025-10-29 | THPharm Corp. | Oral pharmaceutical preparation comprising sodium-glucose cotransporter-2 inhibitor and angiotensin ii receptor blocker |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| WO2007093610A1 (en) | 2006-02-15 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
| TW200904454A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
| AR065809A1 (es) * | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
| JP2011506363A (ja) | 2007-12-11 | 2011-03-03 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 心不全の処置および／または予防用のオキサゾリジノン類 |
| CA2812016A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| MX367404B (es) | 2014-06-30 | 2019-08-20 | Astrazeneca Ab | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. |
| JP2017528499A (ja) * | 2014-09-25 | 2017-09-28 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | 肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤 |
| AU2017233889B2 (en) | 2016-03-16 | 2022-07-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising empagliflozin and uses thereof |
| EP3508222A4 (en) * | 2016-08-30 | 2020-04-29 | Niigata University | MEDICINES FOR REMOVING AGED CELLS |
| WO2018142422A1 (en) | 2017-02-02 | 2018-08-09 | Indoco Remedies Limited | Process for the preparation of dapagliflozin |
| KR101943382B1 (ko) | 2017-09-19 | 2019-01-29 | 오토텔릭바이오 주식회사 | Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물 |
| BR112021000139A2 (pt) | 2018-07-19 | 2021-04-06 | Astrazeneca Ab | Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma |
| WO2021037400A1 (en) | 2019-08-30 | 2021-03-04 | Astrazeneca Ab | Methods of treating heart failure with reduced ejection fraction with dapagliflozin |
| TW202220672A (zh) * | 2020-07-27 | 2022-06-01 | 瑞典商阿斯特捷利康公司 | 用達格列淨治療慢性腎臟病之方法 |
-
2020
- 2020-03-09 WO PCT/EP2020/056211 patent/WO2021037400A1/en not_active Ceased
- 2020-03-09 JO JOP/2020/0098A patent/JOP20200098A1/ar unknown
- 2020-03-09 CA CA3079175A patent/CA3079175A1/en active Pending
- 2020-03-09 PE PE2020000563A patent/PE20211267A1/es unknown
- 2020-03-09 BR BR112020008705A patent/BR112020008705A2/pt not_active Application Discontinuation
- 2020-03-09 SG SG11202003971RA patent/SG11202003971RA/en unknown
- 2020-03-09 US US16/812,745 patent/US10973836B2/en active Active
- 2020-03-09 AU AU2020202887A patent/AU2020202887B2/en active Active
- 2020-03-09 MX MX2020005388A patent/MX2020005388A/es unknown
- 2020-03-09 KR KR1020207012588A patent/KR102359799B1/ko active Active
- 2020-03-09 JP JP2020524303A patent/JP7756487B2/ja active Active
- 2020-03-09 KR KR1020217014553A patent/KR20220044234A/ko not_active Ceased
- 2020-03-09 EP EP20710490.2A patent/EP4021507A1/en active Pending
- 2020-03-09 CR CR20200224A patent/CR20200224A/es unknown
- 2020-03-09 KR KR1020247038499A patent/KR20240166611A/ko active Pending
- 2020-03-09 CN CN202080000531.4A patent/CN112752582A/zh active Pending
- 2020-04-19 IL IL274020A patent/IL274020A/en unknown
- 2020-04-30 TW TW109114687A patent/TWI786398B/zh active
- 2020-04-30 TW TW111145734A patent/TWI859649B/zh active
- 2020-04-30 TW TW113137483A patent/TW202504616A/zh unknown
- 2020-05-01 PH PH12020551141A patent/PH12020551141A1/en unknown
- 2020-05-20 CL CL2020001335A patent/CL2020001335A1/es unknown
- 2020-07-13 MX MX2022008018A patent/MX2022008018A/es unknown
-
2021
- 2021-02-25 US US17/184,746 patent/US11903955B2/en active Active
- 2021-08-10 AU AU2021215150A patent/AU2021215150B2/en active Active
-
2022
- 2022-12-06 JP JP2022194700A patent/JP7494277B2/ja active Active
-
2023
- 2023-07-31 AU AU2023210548A patent/AU2023210548B2/en active Active
-
2024
- 2024-01-11 US US18/410,094 patent/US20240216404A1/en active Pending
- 2024-05-22 JP JP2024083232A patent/JP2024119842A/ja active Pending
-
2025
- 2025-04-04 JP JP2025062458A patent/JP2025108488A/ja active Pending
- 2025-06-17 AU AU2025204486A patent/AU2025204486A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020001335A1 (es) | Métodos de tratamiento de la insuficiencia cardiaca con fracción de eyección reducida con dapagliflozina | |
| CL2020002401A1 (es) | Composiciones de arni de 17 b-hidroxiesteroide deshidrogenasas tipo 13 (hsd17b13) y métodos de uso de las mismas. | |
| CL2020001742A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
| DOP2021000273A (es) | Agonistas del receptor del péptido-1 similar al glucagón | |
| CL2021003374A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
| MX2020004005A (es) | Terapias genicas para los trastornos lisosomales. | |
| CL2013001247A1 (es) | Metodo de tratamiento y/o prevencion del estres oxidativo, estres vascular y/o disfuncion endotelial en pacientes no diabeticos o en pacientes con diabetes tales como de tipo 1, diabetes autoinmune latente del adulto (dala) y diabetes de tipo 2, que comprende administrar linagliptina; compuesto linagliptina, inhibidor de dpp-4. | |
| CL2023001351A1 (es) | Métodos de tratamiento de la insuficiencia cardíaca mediante la administración de omecamtiv mecarbil. | |
| MX366343B (es) | Terapia genetica. | |
| BR112022004699A2 (pt) | Vs-6063 em combinação com ch5126766 para o tratamento de câncer | |
| MX2015012520A (es) | Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion. | |
| NI201700042A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos. | |
| MX351865B (es) | Composiciones de raav-guanilato ciclasa y metodos para el tratamiento de la amaurosis congenita de leber 1 (lca1). | |
| MX2018010852A (es) | Metodos para tratar la depresion con antagonistas del receptor de orexina-2. | |
| MX342409B (es) | Tratamiento de enfermedades cardiacas. | |
| CR20130409A (es) | Novedosos derivados de azabencimidazolcíclico útiles como agentes antidiabéticos | |
| NI201800130A (es) | Moduladores del receptor beta-3 adrenérgico de utilidad para el tratamiento o la prevención de trastornos relacionados con ellos | |
| BR112017010599A2 (pt) | análogos de ureia ligada substituída como moduladores sirtuin | |
| CO2019012125A2 (es) | Inhibidores ip6k | |
| MX2022007670A (es) | Compuestos antihelminticos que comprenden una estructura de quinolina. | |
| MX2021011958A (es) | Terapias genicas para trastornos lisosomales. | |
| MX2017016347A (es) | Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal. | |
| DOP2017000129A (es) | 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa | |
| MX2025003918A (es) | Tratamiento de la disfuncion sistolica | |
| MX2021003904A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj. |